- Home
- PENG vs NBTX Comparison
PENG vs NBTX Comparison
Compare PENG & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | NBTX |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PENG | NBTX |
|---|---|---|
| Price | $20.37 | $22.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $27.50 | $8.00 |
| AVG Volume (30 Days) | ★ 798.6K | 30.6K |
| Earning Date | 01-06-2026 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,368,794,000.00 | $11,930,711.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $15.95 | $145.24 |
| P/E Ratio | $72.46 | ★ N/A |
| Revenue Growth | ★ 16.91 | N/A |
| 52 Week Low | $14.20 | $2.82 |
| 52 Week High | $29.80 | $30.35 |
Technical Indicators
Market Signals| Indicator | PENG | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 58.15 |
| Support Level | $19.65 | $21.44 |
| Resistance Level | $20.27 | $24.01 |
| Average True Range (ATR) | 0.64 | 0.87 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 26.71 | 73.94 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.